T cell receptor-engineered T cells targeting the TP53R248Q neoantigen elicit antitumor effects in human cancer models.

doi:10.1172/JCI196613

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

T cell receptor-engineered T cells targeting the TP53R248Q neoantigen elicit antitumor effects in human cancer models.

The Journal of clinical investigation - 2 Mar 2026

Shen Lianghua, Chen Ziyu, Xu Jian, He Qiaomei, Zhang Changmeng, Zhou Xiao, Ding Xiaodan, Fang Jinan, Li Fanlin, Jiao Ming, Yang Yuqin, Dong Baoxia, Wan Liping, Ding Xueying, Zheng Yan, Zhou Jingyi, Zuo Chijian, Min Tian, Zhu Ming, Ma Bin, Wan Yuhua, Guo Qiufang, Zhang Hua, Hua Jian, Wang Pengran, Li Qi, Long Jiang, Song Xianmin, Zhang Yan

Abstract excerpt

Malignant tumors with TP53 mutations exhibit poor therapeutic outcomes and high recurrence rates. T cell receptor-based (TCR-based) T cell therapy shows great promise for targeting intracellular cancer neoantigens. However, the immunogenic potential of TP53 hotspot mutations remains poorly characterized. Here, we identified an immunogenic neoantigen derived from the recurrent TP53R248Q mutation, presented by the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Line, Tumor

Share to Immunotherapy, Adoptive

Share to Neoplasms

Share to Receptors, Antigen, T-Cell

Share to T-Lymphocytes

Share to Tumor Suppressor Protein p53

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 41528883
DOI: 10.1172/JCI196613
PMCID: PMC12948421

Genes

TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

T cell receptor-engineered T cells targeting the TP53R248Q neoantigen elicit antitumor effects in human cancer models.PMID 41528883Read ↗

Adoptive cell therapy targeting common p53 neoantigens in human solid cancersSemantic proximity Read ↗

Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancersSemantic proximity Read ↗

T-cell Responses to TP53 "Hotspot" Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers.Semantic proximity Read ↗

T cell receptors employ diverse strategies to target a p53 cancer neoantigenSemantic proximity Read ↗

Targeting a neoantigen derived from a common TP53 mutation.Semantic proximity Read ↗

Identification of public neoantigens with broad HLA class I coverage as candidates for off-the-shelf cancer vaccine development in colorectal cancer.Semantic proximity Read ↗

Structural basis for oligoclonal T cell recognition of a shared p53 cancer neoantigen.Semantic proximity Read ↗

Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal CancerSemantic proximity Read ↗

Identification of an HLA-A*11:01-restricted neoepitope of mutant PIK3CA and its specific T cell receptors for cancer immunotherapy targeting hotspot driver mutations.Semantic proximity Read ↗

Revisiting tumor immunogenicity through the lens of mutant p53: Implications for cancer immunotherapy.Semantic proximity Read ↗

Identification of an HLA-A*11:01-restricted neoepitope of mutant PIK3CA and its specific T-cell receptors for cancer immunotherapy targeting hotspot driver mutationsSemantic proximity Read ↗

Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point MutationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.